Bio-Rad Laboratories Inc (NYSE: BIO)’s stock price has soared by 0.67 in relation to previous closing price of 230.46. Nevertheless, the company has seen a gain of 0.79% in its stock price over the last five trading days. globenewswire.com reported 2025-06-17 that International Defense Ministry Awards BIO-key (Nasdaq: BKYI) over $600K in Follow-On Orders for Secure Biometric Access to Critical Information #Biometrics
Is It Worth Investing in Bio-Rad Laboratories Inc (NYSE: BIO) Right Now?
BIO has 36-month beta value of 0.94. Analysts have mixed views on the stock, with 2 analysts rating it as a “buy,” 2 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for BIO is 18.46M, and currently, short sellers hold a 6.62% ratio of that float. The average trading volume of BIO on June 19, 2025 was 389.85K shares.
BIO’s Market Performance
BIO stock saw a decrease of 0.79% in the past week, with a monthly decline of -6.70% and a quarterly a decrease of -8.72%. The volatility ratio for the week is 1.90%, and the volatility levels for the last 30 days are 2.57% for Bio-Rad Laboratories Inc (BIO). The simple moving average for the past 20 days is 2.41% for BIO’s stock, with a -22.25% simple moving average for the past 200 days.
Analysts’ Opinion of BIO
Many brokerage firms have already submitted their reports for BIO stocks, with Citigroup repeating the rating for BIO by listing it as a “Buy.” The predicted price for BIO in the upcoming period, according to Citigroup is $400 based on the research report published on October 01, 2024 of the previous year 2024.
Wells Fargo, on the other hand, stated in their research note that they expect to see BIO reach a price target of $340. The rating they have provided for BIO stocks is “Equal Weight” according to the report published on August 28th, 2024.
Jefferies gave a rating of “Hold” to BIO, setting the target price at $315 in the report published on June 03rd of the previous year.
BIO Trading at -1.71% from the 50-Day Moving Average
After a stumble in the market that brought BIO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -40.20% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BIO starting from Crowley Michael, who sale 3,000 shares at the price of $247.06 back on Mar 14 ’25. After this action, Crowley Michael now owns 8,171 shares of Bio-Rad Laboratories Inc, valued at $741,184 using the latest closing price.
Crowley Michael, the Officer of Bio-Rad Laboratories Inc, proposed sale 3,000 shares at $260.00 during a trade that took place back on Mar 13 ’25, which means that Crowley Michael is holding shares at $780,000 based on the most recent closing price.
Stock Fundamentals for BIO
Current profitability levels for the company are sitting at:
- 0.1 for the present operating margin
- 0.54 for the gross margin
The net margin for Bio-Rad Laboratories Inc stands at -0.88. The total capital return value is set at 0.03. Equity return is now at value -27.51, with -19.55 for asset returns.
Based on Bio-Rad Laboratories Inc (BIO), the company’s capital structure generated 0.17 points at debt to capital in total, while cash flow to debt ratio is standing at 0.38. The debt to equity ratio resting at 0.21. The interest coverage ratio of the stock is 5.08.
Currently, EBITDA for the company is -2.1 billion with net debt to EBITDA at -0.34. When we switch over and look at the enterprise to sales, we see a ratio of 2.82. The receivables turnover for the company is 5983.24for trailing twelve months and the total asset turnover is 0.27. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.99.
Conclusion
To put it simply, Bio-Rad Laboratories Inc (BIO) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
